November 1, 2018

Entos Pharmaceuticals joins JLABS San Diego

Published by:
Entos Pharmaceuticals

Entos Pharmaceuticals is One of the Promising Healthcare Startups Accepted into J&J Innovation JLABS San Diego.

November 1, 2018: The Johnson and Johnson (J&J) company vision is for a World Without Disease and their strategy to reach this goal is summed up by;

1)  earlier/better prevention, 2) early disease interception and 3) cures.

To fuel this vision J&J builds partnerships with innovative companies developing high quality technology that supports an unmet health-related need and fits with J&J’s strategic focus. But J&J doesn’t stop there, they also accept scientifically promising startups into JLABS; their innovation  and incubation program that has nine facilities in the USA, one in Toronto,  Canada and another opening soon in Shanghai, China. Entos Pharmaceuticals is one of four promising Therapeutics-focused startups offered residency into J&J’s flagship innovation facility, JLABS San Diego, that supports 60 startups in total. The program offers lab facilities, mentorship and networking events aimed at helping these emerging companies to succeed.

“We also  incubate startups … they can develop their product without large expenses and  focus on what they are best at: their science and making their idea ready for  the consumer. If then it looks interesting and falls into our strategic  focus, we may sit down and discuss whether they’d like to tighten that  partnership – but they’re completely independent and don’t have to promise us  anything,” Oliver Stohlmann,  J&J’s global head of external innovation communication.

Read more:

JLABS San Diego:

Entos Pharmaceuticals

33 St James's Square
London, UK, SW1Y 4JS

Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

3040 Science Park Road, Suite 1100
San Diego, CA 92121

General Contact
Tel: 1-800-727-0884

Investor Contact

Media Contact

Careers Contact
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.